What is intravenous Immunoglobulin?

Intravenous Immunoglobulin is a treatment that uses human plasma to create antibodies. These antibodies help the body fight infections and other illnesses.

What is the therapeutic use of IVIG?

IVIG can be used to treat many medical conditions including autoimmune diseases, primary immune deficiency disease, and neurological disorders.

IVIG is administered intravenously through the veins of the arm or hands. Infusions can last several hours, depending on dose and patient condition.

What side effects can IVIG have?

Side effects of IVIG include nausea, headaches, fever, chills and muscle or joint pain. These side effects usually resolve themselves.

What factors are driving the IVIG market growth?

Factors such as the growing geriatric population and increasing awareness of IVIG are driving the growth of the IVIG industry.

Global Intravenous Immunoglobulin Market by Type (IgG, IgM, IgA, IgE, And IgD), by Indication (Primary Immunodeficiency, Chronic Inflammatory, Demyelinating Polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), and Immune Thrombocytopenic Purpura (ITP)), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies), by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Published date: Oct 2023
Report ID: 101568
Number of Pages: 218
Format:

- CSL Behring
- Shire (Takeda Pharmaceutical Company Limited)
- Grifols, S.A.
- Kedrion S.p.A
- Octapharma
- Bio Products Laboratory Ltd.
- Biotest AG
- China Biologic Products Holdings, Inc.
- LFB SA
- Shanghai RAAS Blood Products Co., Ltd.
- Other Key Players

Related Reports

Our Clients

Report ID 101568
Published Date Oct 2023
Rating
- ★★★★★
  
  ★★★★★
- (118)

Buy Now

Trusted by more than 17382 organizations globally

✖

Request a Sample Report

We'll get back to you as quickly as possible